Furthermore, among the numerous predictive biomarkers explored for immunotherapy, it would be of interest to investigate changes in the frequency and/or activation status of CD39 + CD8 + TILs in lung cancer patients responding to anti-PD-1 therapies. This evidence concerns the gene CD8A and lung cancer.